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I n this review, the relationship of nevi and melanoma to sun­light will be examined, beginning with a brief overview of mechanisms of carcinogenesis, then considering the phe­nomena of tumor progression as they are observed in the human melanocytic system. Next, epidemiologic and bio­
logic observations implicating UV light in the pathogenesis of mel­
anoma will be discussed, and a hypothesis will be presented impli­
cating UV light as an initiator and promoter of melanocytes, as an 
enhancer of genetic instability and of the mutations associated with 
tumor progression, and as a specific immunosuppressant agent for 
UV -induced tumors. Possible important differences between the 
melanomas that occur in white and non-white populations, and in 
Japanese, will be briefly discussed. 
MECHANISMS OF CARCINOGENESIS 
Initiation In the multistep hypothesis of carcinogenesis, at least 
three stages may be recognized, namely, initiation, promotion, and 
progression [1). Initiation is a process that irreversibly and heritably 
alters a cell, conferring on it the potential for a period of continuous 
growth that is relatively unaffected by normal growth controls. In 
Nowell's terms, the cell has the potential for a "selective growth 
advantage" compared to normal cells [2), but the realization of this 
potential depends on the next step, promotion. 
Promotion Although many carcinogens are "complete" (capable 
of both initiation and promotion), some require the added effect of a 
promoter, an agent that establishes the cell and its progeny as a clone 
characterized by a growth advantage relative to surrounding normal 
cells. A common property of promoting agents is their ability to 
stimulate cell division. For example, in one hepatocellular carcino­
genesis model [3]. partial hepatectomy is used to stimulate division. 
Normal cells divide until the stimulus is withdrawn; initiated cells 
proliferate for a time to form a small morphologically recognizable 
and enzymatically altered focus of cells. This focus is not, however, 
completely autonomous, and its growth is not inexorable - the 
small lesions ultimately enter a period of growth stability. 
Progression and the Enhancement of Genetic Instability 
The initial response to a complete carcinogen, or to initiation and 
promotion, is a benign neoplasm, such as a cutaneous papilloma, a 
benign liver nodule, or a benign melanocytic nevus. Cancer arises 
much later, after a series of stepwise changes in some of these benign 
lesions. Because these changes are hereditary, it is plausible to specu­
late that they are the consequence of genetic alterations in the le­
sional cells, and that such cells may be at special risk of progression 
because of inherent or acquired genetic instability. Genetic instabil­
ity (susceptibility to mutations) may well be a property of the initi­
ated cell from the beginning. As mutations accumulate, the proba-
bility that some will confer additional attributes of the cancer 
phenotype on initiated cells increases. The probability of such mu­
tations will likely be much greater if the clone has been expanded by 
a suitable promotion stimulus (creating a larger pool of cells at risk), 
and the probability may also be enhanced if the carcinogen (a geno­
toxic agent that has already caused at least one mutation in the 
initiated cell) continues to act on the promoted lesion. 
Specific Immunosuppression Although the role of a general 
failure of immune surveillance is not now considered to be of great 
importance in the early stages of carcinogenesis, the work of Kripke 
[4) and others has shown in mice that there may be an important 
specific failure of immune rejection of tumors induced by ultravio­
let light. The mechanism appears to be the induction of specific 
suppressor cells [5), perhaps directed at antigens altered by photo­
chemical effects of UV. These suppressor cells apparently prevent 
the development of cytotoxic effector cells capable of killing the 
tumor. There is some evidence that UV immunosuppression occurs 
in humans as well [6). 
TUMOR PROGRESSION IN THE 
MELANOCYTIC SYSTEM 
Melanocyte The melanocyte is a dendritic cell that is located in 
the epidermis among basilar keratinocytes [7). Its function is the 
synthesis of melanin, and the prompt transfer of this pigment to 
surrounding keratinocytes. Thus, melanocytes rarely contain ap­
preciable amounts of melanin in their own cytoplasm. Although 
melanocytes themselves contain little or no pigment, they are nor­
mally protected from UV light by the melanin in keratinocytes, 
which forms a protective cap over the nucleus. In poorly pigmented 
individuals, this protection is less efficient than in people with more 
pigmented skin. In red-haired individuals, the presence of pheo­
melanin [8) could exacerbate the effects of UV light by the genera­
tion of potentially genotoxic-free radicles [9). In either case, the 
DNA of melanocytes is at risk ofuV light-induced phototoxic and 
potentially mutagenic effects which could act as initiators. Further, 
because UV light is a normal mitogenic stimulus for melanocytes 
[10]. it could serve as a promoting agent as well, and thus as a 
complete carcinogen. 
Common Nevus The common melanocytic nevus is almost 
ubiquitous in mankind. The average number of nevi in whites 
reaches about 15 - 30 in normal individuals by the late teenage years 
[11). Nevi evolve as small, brown lesions in the skin and undergo a 
characteristic evolution [12). The earliest lesion is termed a "lentigo 
simplex." It is less than 2 - 3 mm in diameter, symmetrical, circum­
scribed, and uniformly colored brown or sometimes almost black. 
Such lesions may remain completely stable for years or may evolve, 
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with the appearance of nests in the epidermis, into a junctional 
common acquired nevus. As these nests migrate into the dermis, the 
same lesion is termed a compound nevus, and ultimately completes 
its evolution as a dermal nevus. 
Our hypothesis of tumor progression in the melanocytic system 
proposes that the common nevus (or, more exactly, its precursor, 
the lentigo) is the initiated and promoted response to a carcinogenic 
stimulus. The stimulus is considered usually, but not always, to be 
ultraviolet light. It should not be surprising that a ubiquitous, be­
nign lesion is induced by a "carcinogen." In experimental chemical 
carcinogenesis the initial response is seen in the form of myriads of 
benign, small lesions that do not grow inexorably [3]. Frank cancer 
occurs much later, after a period in which heritable changes occur in 
some of the cells of a few of these lesions, which are therefore 
"potential precursors" of the malignant tumor itself. Remnants of 
the dermal component of a common acquired nevus are seen often 
in relation to melanomas, consistent with the idea that nevi are also 
potential precursors of cancer [13]. However, clinical and statistical 
evidence suggests that it is very rare for melanoma to evolve directly 
in a common nevus. An intermediate step, melanocytic dysplasia, is 
usually required, and this is the lesion that characterizes "dysplastic 
nevi." Although dysplastic nevi are potential precursors of mela­
noma, the frequency of progression in these lesions is quite low. 
Dysplastic Nevus Dysplastic nevi are, on the average, larger than 
common acquired nevi, and less orderly in their architectural con­
figuration [12,14], exhibiting slight to moderate pigment variega­
tion and border irregularity with an ill-defined, "fuzzy" margin 
[15]. They are mostly flat, but often may have focal, usually central, 
elevation. Dysplastic nevi usually develop from puberty into young 
adulthood, although a few new lesions may continue to appear 
throughout life. Although they are more likely to occur on usually 
covered skin (buttock, breast in women) than common nevi, dys­
plastic nevi are preferentially distributed on sun-exposed surfaces, 
consistent with the idea that they are induced by light [16]. Evolv­
ing dysplastic nevi grow for a time, but, once fully evolved, they are 
completely stable in most instances. 
Dysplastic nevi are biologically benign lesions, and most of them 
are clinically stable. Their main clinical significance is as markers of 
risk for melanoma, and this risk is modified by other phenotypic 
factors such as skin color, and, most importantly, by genotypic 
factors. Patients who have dysplastic nevi and a family history of 
melanoma in two or more relatives have a lifetime risk for mela­
noma of the order of 100% [17] Gust as patients with familial polyp­
osis of the colon may have a 100% risk of colon cancer). By contrast, 
patients with dysplastic nevi who lack this family history have a risk 
increased by a factor of 10 - 20, similar to the risk of individuals who 
have red hair and a propensity to sunburn [18]. 
From the viewpoint of tumor biology, an important attribute of 
dysplastic nevi is their potential role as precursors of melanoma. 
Although most dysplastic nevi are stable, it is also true that as many 
as 25% of melanomas arise in a precursor dysplastic nevus 
[13,19,20]. This paradox can be explained by the fact that dysplastic 
nevi are much more common than melanomas. About 5% of the 
white population has a few to many dysplastic nevi [18]. In a popula­
tion the size of the United States, for example, there may be 10 
million people with an average of up to 10 dysplastic nevi each. In 
the United States population, about 25,000 new melanomas occur 
annually, only 25% of which arise in one of this vast pool of poten­
tial precursor dysplastic nevi. Thus, from a clinical perspective, 
dysplastic nevi should not be managed as if they were at particularly 
high risk of progression to melanoma. 
Histologically, dysplastic nevi differ from common nevi in their 
architectural features, and in the presence of cytologic atypia in a 
minority of the lesional cells. Atypia may be difficult to find in some 
lesions. However, just as the diagnosis of Hodgkin's disease depends 
on the Reed-Sternberg cell which is a necessary, but not sufficient, 
feature, the diagnosis of a dysplastic nevus should be made with 
caution in the complete absence of atypia. Although atypia is of 
diagnostic importance in dysplastic nevi, these are not floridly atyp-
THE JOURNAL OF INVESTIGATIVE DERMATOLOGY 
ical lesions as a rule [14]. Nevertheless, the atypia is probably of 
fundamental biologic significance. There is evidence that the mild 
cytologic atypia characteristic of a dysplastic nevus does reflect ab­
normalities at the DNA level. Morphometric studies have shown 
that dysplastic nevi take an intermediate position between common 
nevi and melanomas with respect to DNA content measured cyto­
fluorimetrically, as well as to melanosome morphology and to cel­
lular area and perimeter measurements [21-23]. Further, some dys­
plastic nevi exhibit chromosomal abnormalities in tissue culture 
[24,25], although, so far, screening for known oncogenes has 
proven essentially noncontributory [26,27]. The chromosomal ab­
normalities are consistent with the hypothesis that dysplastic nevi 
constitute a reservoir of neoplastic melanocytes at the risk of acquir­
ing additional mutations. The risk of such mutations is presumably 
much higher than in common nevi. In a few of these dysplastic nevi, 
some of these mutations may contribute to the "cancer phenotype," 
and thus account for the occasional observation of progression to 
melanoma [28]. 
Microinvasive Melanoma (Radial Growth Phase) Tumor 
progression does not end with the establishment of the diagnosis of 
primary melanoma and, indeed, probably continues in metastatic 
disease as well. Primary melanomas evolve through at least two 
clearly defined stages. In the first stage, characterized by progressive 
autonomous growth without tumorigenicity or the capacity for 
metastasis [29]' the lesion is a patch or plaque that expands at its 
periphery. This stage has been termed the "radial growth phase" 
because the lesion expands centrifugally along the radii of an imper­
fect circle [30]. The lesional cells are confined to the epidermis (in 
situ) or extend as small groups or single cells into the papillary 
dermis, a process that may be termed "microinvasion." However, 
there is no true mass lesion or tumor. Thus, the evidence suggests 
that these cells are adapted for autonomous growth in the epidermis, 
and for survival but not progressive growth in the dermis. 
Like the cells of dysplastic nevi, those of micro invasive mela­
nomas exhibit cytologic atypia, but this is generally rather more 
severe (usually "moderate" rather than "slight"), and involves a 
majority of the lesional cells ("uniform" rather than "random"). In 
vitro, nonclonal cytologic abnormalities have been discovered in 
the few lines that have been satisfactorily examined. Again similar 
to dysplastic nevi, the cells of micro invasive melanomas are difficult 
to establish in culture, do not form permanent cell lines, grow to a 
low cell density, and are non-tumorigenic in nude mice [31,32]. 
Thus, they do not exhibit the properties of a fully transformed cell. 
Using a panel of monoclonal antibodies, we have recently demon­
strated that the antigenic profile of microinvasive melanoma resem­
bles that of dysplastic nevi rather than of fully evolved tumorigenic 
melanomas (see below) [33]. 
It is generally believed that a high, but unknown, percentage of in 
situ melanomas will grow inexorably and progress to microinvasive 
radial growth-phase melanoma, and then to the tumorigenic (verti­
cal-growth) phase, with formation of a nodule and acquisition of 
competence for metastasis [34]. However, such progression may 
occur very late, often months or years after the onset of the radial 
growth-phase plaque, and in situ and microinvasive melanomas in 
the radial growth phase are biologically benign lesions that do not 
metastasize or recur if they have been completely excised [29]. All of 
these properties are consistent with the idea that micro invasive mel­
anomas represent lesions that are continuing to accrue both addi­
tional mutations of DNA, and additional properties of the trans­
formed phenotype. 
Tumor-Phase Melanoma (Vertical-Growth Phase) Tumor 
phase refers to the acquisition of a new property by the evolving 
melanoma, characterized by the appearance of an expansile nodule 
somewhere within the spreading plaque of radial-phase melanoma. 
This stage of evolution of melanoma can also be termed the "nod­
ule" or the "verticle-growth" phase. The growth is termed "verti­
cal" because there is a tumor nodule that elevates the skin surface, 
extending outward vertically or perpendicular to the skin surface. 
The tumor phase is of great clinical and biologic importance because 
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it is the appearance of a tumor mass that heralds the development of 
a fully evolved neoplasm that has some statistically predictable po­
tential for metastasis [29,30]. In vitro cells from the tumor phase of 
primary melanomas exhibit all of the properties of the fully trans­
formed cell [31,32]. They are immortal in culture, growing to a 
high cell density. They exhibit anchorage-independent growth in 
soft agar with a high plating efficiency, are tumorigenic (and may 
metastasize) in nude mice, and chromosomal analysis shows multi­
ple random and nonrandom abnormalities. These cells can be 
grown in defined media, and produce tumor growth factors. 
It is likely that most tumor-phase melanomas will grow inexora­
bly, progressively, and increasingly rapidly, often with the develop­
ment of multiple nodules and appearance of new populations of 
cells (clonal heterogeneity). As the lesion becomes larger and 
thicker, the number and severity of risk factors such as ulceration, 
level IV or V invasion, high mitotic rate, or microscopic satellites 
increases. These clinical properties are consistent with the progres­
sive acquisition of heritable genetic abnormalities, presumably due 
to increasing genetic instability as time passes. 
Bulky tumor-phase nodules are easily recognized histologically, 
as well as clinically [30]. The pathology is that of cancer anywhere: a 
contiguous mass of large, cytologically atypical, mitotically active 
cells exhibiting a destructive relationship to the surrounding tissues 
and, when large, showing necrosis and surface ulceration. Smaller 
tumor-phase nodules or papules, less than 1 mm in thickness and 
often failing to fill and expand the papillary dermis (level II inva­
sion) are more difficult to recognize with specificity. Generally, the 
presence of a nest in the dermis larger than the largest intraepider­
mal nest implies that there has been proliferation of cells in the 
dermis (tumorigenicity). Melanomas with definite tumor phase 
(vertical growth, as defined histologically), no matter how thin they 
may be, appear to have up to a 10%-15% risk of metastasis, which 
remains approximately constant up to a thickness of about 1.5 mm, 
and then increases progressively with thickness [29,30]. 
EVIDENCE FOR ROLE OF SUNLIGHT IN 
MELANOMA ETIOLOGY 
This section will consider the body of epidemiologic evidence that 
implicates exposure to ultraviolet light as a major cause of human 
cutaneous melanoma, at least in white populations. 
Higher Incidence in Fair-Skinned Races Every epidemiologic 
study that has addressed the question has observed a much higher 
incidence of melanoma in fair-skinned races. For example, a 1986 
survey of 614 United States hospitals studied 4545 melanoma pa­
tients and found that 98% of the patients were white [35]. Within 
white populations, there are differences in melanoma incidence that 
appear to correlate with skin pigmentation. In a recent Australian 
study [36], skin color was measured with a reflectometer, revealing 
elevated incidence rates in individuals with fair skin color of the arm 
compared to darker skin. The melanomas that do occur in non­
whites and in Japanese have a completely different site distribution. 
Most of them occur on plantar skin [37,38], a site that is not only 
rarely exposed to light, but is protected by a thick keratin barrier. 
This fact suggests that plantar melanomas may be related to an 
etiologic agent other than light. 
Higher Incidence in Lower Latitudes In nations with homoge­
neous, predominantly fair-skinned populations, incidence rates for 
melanoma in general are higher in populations living closer to the 
equator. The association with latitude, and thus with presumptive 
UV exposure, suggest that melanoma is associated with sunlight. 
Some studies, particularly within Europe, have failed to show this 
association, perhaps because pigmentary differences were not ac­
counted for [39]. For example, the incidence in Sweden is higher 
than in Southern Europe, perhaps because the Swedish are a more 
homogeneous fair-skinned population than the Mediterranean pop­
ulation. Within Scandinavia, the usual latitude gradient has, indeed, 
been observed [40,41]. In a society like Japan, where most mela­
nomas are plantar, one would predict that this gradient would not 
exist. 
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Gender Differences in Anatomical Site Distribution Most 
epidemiologic studies that have examined the site distribution of 
melanomas have found them to be more common in females on the 
leg (especially the calf ), and in men on the back [35]. Although 
these sites are less heavily exposed to light than areas like the head 
and neck, forearms and hands, most investigators have concluded 
that the site distribution is consistent with intermittent exposure to 
light of susceptible (not-tanned) skin, and that the gender differ­
ences are consistent with differences in clothing styles between the 
two sexes [42]. As noted above, racial differences in site distribution 
also exist. In black and Oriental populations, melanomas are un­
common at all sites, and most of those few melanomas that occur are 
found on palmar-plantar skin or on mucous membranes [37,38]. 
Skin Reaction to Sun Most of the epidemiologic studies that 
have considered skin color as a risk factor for melanoma have found 
incidence to be higher in individuals with "fair" skin. This has been 
measured subjectively or, in one case-control study, by means of a 
reflectometer [38]. There may also be an interaction with red hair 
color [43], and in some studies, red hair color was the strongest 
phenotypic risk factor [44]. The reaction to sun exposure, catego­
rized into groups ranging from ("always burns, never tans" to 
"always tans, never burns") has been associated in most studies with 
increased risk [38,44-46], though this association does not always 
persist after correction for skin and/or hair color [43]. Taken as a 
whole, though, these studies suggest that melanomas are more 
likely to occur in people whose skin is particularly susceptible to 
sunburn, a result that is consistent with a solar etiology for mela­
noma. Characterization of the solar reactivity of a Japanese popula­
tion would be of interest in this regard. 
History of Sunburn Many case-control studies have associated a 
history of sunburn, especially in childhood, with increased risk for 
melanoma [46 - 50]. However, this association disappears in several 
studies after correction for possible confounding variables, espe­
cially hair and skin color, and chronic and acute reaction to sunlight. 
Elwood et al [51] evaluated vacation sun exposure and found an 
increasing trend for melanoma incidence with increasing number 
and severity of sunburn episodes. This association was weakened 
when the confounding variables mentioned above were controlled 
in a multivariate analysis, suggesting that there are strong interac­
tions among sun exposure, sunburn history and pigmentary charac­
teristics. 
Sun Exposure in the First Ten Years of Life In Holman and 
Armstrong's case-control study, melanoma risk increased with du­
ration of residence in the sunny climate of Western Australia [52]. 
Among migrants, age of arrival in this climate was a better predictor 
than duration of residence. The risk of melanoma in migrants arriv­
ing before the age of ten was high, similar to that for native-born 
Australians, while that for later arrivals was lower, and the young 
migrants also had an increased number of benign nevi. The authors 
postulated that early childhood was a crucial age in establishing risk 
for melanoma, and this risk was associated with induction of nevi. In 
terms of a carcinogenesis model, then, exposure to light at an early 
age may be more successful than later exposure in invoking a large 
pool of "potential precursor" lesions (benign nevi). Because most 
native-born Australians, like the migrants, are of British descent, 
the authors considered it difficult to propose a factor other than 
greater exposure to sunlight in childhood that could account for 
these differences. 
Sun Exposure in Young Adulthood Holman and Armstrong 
[52] evaluated sun exposure by age and found that increased risks 
were associated with high exposure in the age periods 10 - 24 and 
25 - 39. Solar exposure was estimated in terms of mean annual sun­
shine hours at each residence. By contrast, total outdoor exposure to 
sunlight (recreational or occupational) was not associated with mel­
anoma risk compared to local controls in this sun-loving Australian 
community. In Western Canada, Elwood et al [51] found no associ­
ation with occupational sun exposure, but recreational exposure was 
associated with increased risk even after controlling for pigmentary 
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variables, consistent with the idea that melanoma risk is increased by 
intermittent exposure of susceptible skin to sunlight, particularly in 
young adult life. These data and the data reviewed above suggest 
that sun exposure occurring several decades before the peak onset of 
melanoma is of etiologic significance, consistent with knowledge 
about the long latency of carcinogenesis, and with the stepwise 
hypothesis of tumor progression in the melanocytic system re­
viewed above. 
Evidence of Actinic Skin Damage Although most cases of 
melanoma in young adults do not show histologic evidence of ac­
tinic damage, Holman and Armstrong [53], using the more-sensi­
tive technique of cutaneous micro-topography, found actinic dam­
age of the skin to be a significant risk factor for melanoma. The odds 
ratios increased progressively with worsening skin condition, rang­
ing up to 4.37 for high-grade damage. This result provides direct 
evidence for an association between a dose of UV light actually 
received in the dermis, near the site of the target melanocytes in the 
basal lamina region, and complements the physiologic evidence 
relating to sunburn susceptibility and incidence. 
Numerous, Large, Irregular Variegated Nevi In Holman and 
Armstrong's Australian case-control study [38], the single strongest 
risk factor for melanoma was the number of palpable nevi on the 
subjects' forearms. The relative risks compared to people with no 
nevi ranged from 2.0 for 1 - 4  nevi to 11.3 for 10 or more nevi. In 
Scotland, very high relative risks were associated with variegation 
of color (RR = 36.41), and irregular edge (43.49) in nevi [54,55]. 
The presence of large nevi and of increasing numbers of nevi were 
also associated with increased risk in this and in other studies 
[56,57]. In sum, the data clearly demonstrate that people with an 
increased number of nevi are at markedly increased risk of mela­
noma, and are consistent with the hypothesis that nevi are either 
markers of exposure to the carcinogen for melanoma, or potential 
precursors of melanoma, or both. 
Dysplastic Nevi In a study of 401 members of 14 hereditary 
melanoma families, dysplastic nevi were a perfect marker of risk for 
prospectively diagnosed melanomas [15]. The lifetime risk for mel­
anoma approached 100% in members with dysplastic nevi, and no 
prospectively diagnosed melanomas were found in patients with 
normal nevi. Hereditary melanoma, an autosomal dominant syn­
drome [58], could account for as much as 5% - 10% of all mela­
nomas in the population, but most melanomas occur outside this 
context. There is evidence that dysplastic nevi are involved in the 
pathogenesis of these "sporadic" melanomas as well. Dysplastic 
nevi have been identified in normal population members in several 
studies, with a frequency ranging from 2% to 14% (average about 
5%) [59 - 63], while the incidence in patients with sporadic mela­
noma in the Pigmented Lesion Clinic at the University ofPennsyl­
vania is about 50% [64]. Using this information, it can be estimated 
that the average risk for all patients with dysplastic nevi who are not 
members of hereditary melanoma kind reds may be elevated by a 
factor of between 10 and 20 [18], much less than the factor of about 
400 that has been reported in the familial situation [15]. In a Scottish 
case-control study, the incidence of dysplastic nevi was 21/131 in 
(mostly nonfamilial) cases and zero in controls [54]. Thus, dysplastic 
nevi were perfect markers of risk in this study as well. Formal 
case-control or longitudinal studies are needed to determine this risk 
more precisely, as well as the factors that may modify it. Dysplastic 
nevi appear to be much less common in Japanese than in other white 
populations [65]. Because they have been associated, for the most 
part, with melanomas of the trunk and limbs, they may have only 
slight significance in the Japanese population, where acral mela­
nomas predominate. 
LABORATORY DATA IN HEREDITARY 
MELANOMA FAMILIES 
The identification of kindreds at increased risk for melanoma has 
led to a number of laboratory studies in an effort to determine the 
genetic mechanism of carcinogenesis. Although these data are most 
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specifically applicable to these high-risk families, it is likely that 
similar mechanisms may operate in sporadic melanoma as well, 
albeit at a lower rate. 
Xeroderma Pigmentosum Xeroderma pigmentosum is an au­
tosomal recessive genetic disorder that has been associated with a 
variety of DNA repair defects. The disease is characterized clinically 
by excessive sun sensitivity, and biologically by cellular hypersensi­
tivity to the lethal and mutagenic effects of UV radiation. These 
effects are all related to a defect in the ability to repair pyrimidine 
dimers. Patients with xeroderma pigmentosum experience a risk for 
melanoma of the order of 2000-fold compared to normal popula­
tions [66]. Thus, xeroderma pigmentosum families may present as 
hereditary melanoma kindreds. The mechanism of solar sensitivity 
in these kindreds differs from that in the more-common form of 
hereditary melanoma that is associated with classic dysplastic nevi. 
Nevertheless, xeroderma patients may have benign pigmented le­
sions on their skin that are similar or identical to dysplastic nevi, and 
also may have common acquired nevi [67]. Thus, this disease pro­
vides a model for a genetic susceptibility to UV light that results in 
the induction of benign, atypical, and malignant melanocytic le­
sions, suggesting that similar or analogous mechanisms may operate 
in the general population as well, and especially in that segment of 
the general population that is affected by dysplastic nevi. 
Families with Hereditary Cutaneous Melanoma and Dys­
plastic Nevi Because it was known that cells from patients with 
xeroderma pigmentosum were sensitive to killing in vitro by UV 
light, Smith et al [68] investigated fibroblasts from five familial 
melanoma/dysplastic nevi families. These cells showed enhanced 
killing compared with normals, but the effect was less than in con­
current positive controls from xeroderma patients. There was no 
demonstrable defect in DNA repair, and no excess sensitivity to 
gamma irradiation. These results suggested a mechanism other than 
pyrimidine dimer formation for the UV sensitivity. 
Although DNA repair appears normal by current methods in 
hereditary melanoma/dysplastic nevus patients, it is possible that 
the repair mechanism might be prone to error in their cells. Perera et 
al [69] investigated this possibility by examining mutagenesis at the 
hypoxanthine-guanine phosphoribosyl transferase locus in Iym­
phoblastoid cell lines from these patients. They found a dose-related 
increase in mutants with increasing UV radiation, suggesting that 
the DNA repair process may be error prone in these families. This 
result provides direct evidence for constitutional genetic instability 
in members of kindreds who are at very high risk of developing 
malignant melanoma. 
HYPOTHESIS: THE FOUR MECHANISMS OF UV 
MELANOCARCINOGENESIS 
A hypothesis of melanoma pathogenesis may be based on effects of 
ultraviolet light acting by four different mechanisms, namely initia­
tion and promotion of the normal melanocyte, followed by the 
induction and/or enhancement of genetic instability, leading to 
progression of the induced and promoted lesions, all occurring in 
association with specific immunosuppression. 
Initiation of the Normal Melanocyte by DNA Damage (No 
Evident Lesion) Abundant clinical and experimental evidence 
demonstrates that UV light is causally related to non-melanoma 
skin cancers [70], and that it can cause DNA damage including 
mutations [71]. The evidence from xeroderma pigmentosum and 
dysplastic nevi patients suggests that these individuals are more 
susceptible to UV -induced genetic damage in exposed cells, pre­
sumably including melanocytes, and they are also more susceptible 
to melanoma. By analogy, it would seem likely that similar mecha­
nisms may be involved (though with lower frequency) in "normal" 
individuals. A large body of epidemiologic data, reviewed above, 
suggests strongly that melanoma in both the familial and the spo­
radic settings is related to UV exposure. All of these data are consist­
ent with the idea that the mechanism of action of UV light is one of 
genetic damage to melanocytes. Analogies with systems such as 
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experimental hepatic carcinogenesis (3) would suggest that the ini­
tial lesion is a point mutation of DNA that is not visible clinically or, 
indeed, microscopically. 
Promotion of the Initiated Melanocyte by Mitogenesis (Solar 
Nevogenesis) Promoting agents are a diverse set of physical and 
chemical activities whose mechanisms are probably equally diverse. 
One property that is common to many of them, however, is the 
stimulation of cell proliferation. For example, partial hepatectomy 
is a promoting agent for foci of hepatocytes that are initiated by 
chemical carcinogens in the rat liver (3). Thus, it may be necessary 
that a round of cell proliferation occurs after initiation to "fix" the 
alteration in the DNA. The altered cells presumably have a selective 
growth advantage (compared to normal cells) in the environment of 
the promoting agent. If proliferation is a mechanism of promotion 
in the melanocytic system, then UV light, a mitogen for normal 
melanocytes, is capable of effecting cell division, and thus of acting 
as a promoter of the melanocyte that has been initiated by the 
genotoxic effects of earlier UV exposure. Melanocytic nevi have all 
of the properties of an initiated and promoted lesion. They are 
potential precursors and markers of risk for melanoma, and yet are 
present in very large numbers compared to frank melanomas. 
Enhancing Genetic Instability by Continued DNA Damage 
(Dysplasias, Melanomas) Although it has been postulated that 
the pigmentation of the initiated and promoted melanocytic lesion 
(the nevus) is an adaptive response that tends to protect these neo­
plastic cells from the continued adverse effects of UV light (7), this 
mechanism is presumably imperfect in some circumstances. Thus, 
the lesional cells in nevi may be at risk of continued DNA damage. 
Some of these DNA lesions may cause mutations that result in 
phenotypic alterations of the nevus cells, including the appearance 
of cellular atypia and the progressive acquisition of the "cancer" 
phenotype. This effect may be exacerbated by genetic instability, 
either constitutional in the case of familial melanoma kindreds, or 
acquired as a consequence of initiation and/or promotion. Thus, 
UV light, in addition to its role in nevogenesis, might continue to 
act as an enhancer of genetic instability, increasing the chance that 
the series of mutations that result in invasion and metastasis will 
occur in these cells. 
Specific Immunosuppression by Induction of Suppressor 
Cells (Dysplasias, Melanomas) Evidence of a host-immune re­
sponse to melanocytic lesions first appears (in terms of the postu­
lated tumor progression sequence presented here) in dysplastic nevi, 
is maximal in micro invasive melanomas, and becomes less evident 
in the tumor stage [30). The phenotype of these reactive lympho­
cytes includes cells with markers of cytotoxic and of suppressor cells 
(72). In some melanomas, there is evidence of effective cellular 
cytotoxicity in the form of partial regression of microinvasive mela­
nomas (7). However, this response is rarely completely effective in 
eliminating the tumor. This impotence of the immune response in 
the face of an evolving neoplasm could be due to many factors, 
including properties of the tumor cells themselves. However, if the 
UV tumor-associated induction of suppressor cells that has been 
described above in the murine model occurs also in the human 
setting, it could be that the continued action of UV light not only 
permits the development of these atypical cellular lesions, but also 
enhances the pace of their evolution. 
SUMMARY AND CONCLUSIONS 
Two hypotheses have been presented. The first states that mela­
nomas commonly evolve from normal melanocytes by a tumor pro­
gression pathway from a banal nevus to a nevus with dysplasia, to a 
micro-invasive, and then to a fully evolved, tumorigenic, primary 
melanoma which has competence for metastasis. It is important to 
note that not all melanomas follow this complete pathway. As 
Foulds (73) noted long ago, tumors may bypass any of the stages of 
tumor progression. Thus, many melanomas do not, apparently, 
arise in nevi, and melanomas may evolve "fully formed" as pure 
tumorigenic nodules. However, from the biological point of view, 
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study of the benign potential precursors (nevi and, especially, dys­
plastic nevi as well as microinvasive melanomas) may well reveal 
mechanisms of progression that are applicable to all melanomas, and 
perhaps to other solid tumors as well. From a clinical viewpoint, 
follow-up and education of patients at increased risk for melanoma, 
and early diagnosis of melanomas in their curable, microinvasive 
stages may result in a reduction of mortality from the disease, even 
without influencing its overall incidence. The melanomas that 
occur on plantar and palmar (acral) skin appear to progress through a 
microinvasive stage similar to that of other cutaneous melanomas. 
However, the significance of precursor and marker lesions (if any 
exist) in acral melanoma remains to be elucidated by clinicopatho­
logic and epidemiologic studies. The possibility of etiologic agents 
other than UV light, such as chemical carcinogens and/or viruses, 
should be investigated in these cases. 
The second hypothesis presented here, that UV light is etiologic 
for the common cutaneous melanoma of white populations, has 
support from clinical, epidemiologic, and biologic observations. 
From a biologic viewpoint, ultraviolet light has all of the properties 
that might enable it to act as a complete carcinogen, and to enhance 
tumor progression in melanocytic "potential-precursor" lesions. 
Clinically, it seems appropriate to encourage patients (and members 
of the general population, as well) to adopt sensible attitudes to sun 
exposure. By such means, it is possible that some melanomas might 
be prevented, or that the rate and incidence of progression to more­
advanced stages might be inhibited. 
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